Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
The First Bancorp Inc is a banks-regional business based in the US. The First Bancorp shares (FNLC) are listed on the NASDAQ and all prices are listed in US Dollars. The First Bancorp employs 250 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$29.12|
|52-week range||$20.40 - $32.28|
|50-day moving average||$29.02|
|200-day moving average||$29.41|
|Wall St. target price||N/A|
|Dividend yield||$1.25 (4.23%)|
|Earnings per share (TTM)||$2.89|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-2.02%|
|1 month (2021-09-15)||6.28%|
|3 months (2021-07-15)||1.43%|
|6 months (2021-04-15)||0.17%|
|1 year (2020-10-15)||27.00%|
|2 years (2019-10-15)||6.28%|
|3 years (2018-10-15)||2.21%|
|5 years (2016-10-14)||28.34%|
Valuing The First Bancorp stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of The First Bancorp's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
The First Bancorp's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, The First Bancorp shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||$77.2 million|
|Operating margin TTM||50.86%|
|Gross profit TTM||$71.9 million|
|Return on assets TTM||1.35%|
|Return on equity TTM||14.1%|
|Market capitalisation||$326.6 million|
TTM: trailing 12 months
There are currently 107,248 The First Bancorp shares held short by investors – that's known as The First Bancorp's "short interest". This figure is 9.7% up from 97,779 last month.
There are a few different ways that this level of interest in shorting The First Bancorp shares can be evaluated.
The First Bancorp's "short interest ratio" (SIR) is the quantity of The First Bancorp shares currently shorted divided by the average quantity of The First Bancorp shares traded daily (recently around 14711.659807956). The First Bancorp's SIR currently stands at 7.29. In other words for every 100,000 The First Bancorp shares traded daily on the market, roughly 7290 shares are currently held short.
However The First Bancorp's short interest can also be evaluated against the total number of The First Bancorp shares, or, against the total number of tradable The First Bancorp shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case The First Bancorp's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 The First Bancorp shares in existence, roughly 10 shares are currently held short) or 0.0129% of the tradable shares (for every 100,000 tradable The First Bancorp shares, roughly 13 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against The First Bancorp.
Find out more about how you can short The First Bancorp stock.
Dividend payout ratio: 41.31% of net profits
Recently The First Bancorp has paid out, on average, around 41.31% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.29% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), The First Bancorp shareholders could enjoy a 4.29% return on their shares, in the form of dividend payments. In The First Bancorp's case, that would currently equate to about $1.25 per share.
While The First Bancorp's payout ratio might seem fairly standard, it's worth remembering that The First Bancorp may be investing much of the rest of its net profits in future growth.
The First Bancorp's most recent dividend payout was on 21 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 7 October 2021 (the "ex-dividend date").
The First Bancorp's shares were split on a 3:1 basis on 1 June 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your The First Bancorp shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for The First Bancorp shares which in turn could have impacted The First Bancorp's share price.
Over the last 12 months, The First Bancorp's shares have ranged in value from as little as $20.4025 up to $32.2755. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while The First Bancorp's is 0.5825. This would suggest that The First Bancorp's shares are less volatile than average (for this exchange).
The First Bancorp, Inc. operates as the holding company for First National Bank that provides a range of banking products and services to individual and corporate customers. It offers various deposit products, including demand, NOW, savings, money market, and certificates of deposit accounts. The company also provides commercial loan products, such as mortgage loans to finance investments in real property comprising multi-family residential, commercial/retail, office, industrial, hotel, educational, and other specific or mixed use properties; loans to finance construction of owner- and non-owner occupied commercial real estate properties; and revolving and term loan obligations to business and corporate enterprises for the purpose of financing working capital or capital investment. In addition, it offers municipal loans for capitalized expenditures, construction projects, or tax-anticipation notes; residential term loans that include amortizing home mortgages and construction loans, which include loans for owner-occupied residential construction; home equity loans and lines of credit; and consumer loans, which are amortizing loans to individuals collateralized by automobiles, pleasure crafts, and recreation vehicles, as well as unsecured short-term time notes. Further, the company provides private banking, financial planning, investment management, and trust services to individuals, businesses, non-profit organizations, and municipalities, as well as ATM processing services. It operates through 17 full-service banking offices in Lincoln, Knox, Waldo, Penobscot, Hancock, and Washington counties in the Mid-Coast, Eastern, and Down East regions of Maine.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.